drugset / Trial / NCT04720976
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Timeline
- Start
- 2021-03-23
- Primary completion
- 2023-12-19
- Completion
- 2023-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | — | Oral |
| Subject | JAB-3312 | Unknown | — | Oral |
| Subject | Osimertinib | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Sotorasib | Small molecule | — | Oral |